Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
14/11/2025
Jahwa Biotech Holdings Limited has submitted its listing application to the Hong Kong Stock Exchange.
Latest
2 m ago
Cidara Therapeutics' pre-market stock increase has expanded to 105%, with Merck & Co. set to acquire the company for $221.5 per share in cash. The transaction is expected to be completed in the first quarter of 2026.
2 m ago
New stock news | Yingpai Pharmaceuticals plans to list in Hong Kong. The China Securities Regulatory Commission requires additional clarification on matters such as past capital increases and pricing basis for equity transfers.
2 m ago
Ministry of Finance: Promote financial reform management and accelerate the construction of a high-level socialist market economy system.
2 m ago
New Stocks Update | Wan Yuan Technology Plans to List on the Hong Kong Stock Exchange. The China Securities Regulatory Commission Requires Supplementary Explanation of the Company's Historical Background and Other Matters.
2 m ago
New Stock News | Rongtai Pharmaceuticals Plans to List in Hong Kong. China Securities Regulatory Commission requires additional explanation on the reasonableness of the price at which new shareholders have entered in the past year.
See all latest